Literature DB >> 19067103

Combined plasmapheresis and high-dose intravenous immunoglobulin treatment in systemic sclerosis for 12 months: follow-up of immunopathological and clinical effects.

Zoltán Szekanecz1, Magdolna Aleksza, Péter Antal-Szalmás, Pál Soltész, Katalin Veres, Sándor Szántó, Zoltán Szabó, Anikó Végvári, Szilvia Szamosi, Gabriella Lakos, Sándor Sipka, Gyula Szegedi, John Varga, Gabriella Szücs.   

Abstract

Systemic sclerosis (SSc) is an autoimmune disease which involves the skin, as well as several internal organs. Most therapies available in this disease are symptomatic. Authors present a case of diffuse SSc with progressive disease not responding to currently available treatments. Therefore a 12-month protocol of repeated plasmapheresis and high-dose intravenous immunoglobulin treatment was administered with good clinical efficacy. Apart from monitoring the clinical symptoms throughout the treatment, authors also assessed a number of humoral and cellular immunolaboratory markers in order to obtain information on the immunomodulatory effects of this combined treatment in SSc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19067103     DOI: 10.1007/s10067-008-1062-2

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  9 in total

1.  [Plasmapheresis therapy in systemic sclerosis].

Authors:  Gabriella Szúcs; Szilvia Szamosi; Magdolna Aleksza; Katalin Veres; Pál Soltész
Journal:  Orv Hetil       Date:  2003-11-09       Impact factor: 0.540

2.  Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study.

Authors:  Yair Levy; Howard Amital; Pnina Langevitz; Francesca Nacci; Anna Righi; Letizia Conforti; Sergio Generini; Marco Matucci Cerinic; Yehuda Shoenfeld
Journal:  Arthritis Rheum       Date:  2004-03

3.  [Three patients with systemic sclerosis complicated by microangiopathic hemolytic anemia and thrombocytopenia].

Authors:  A Mimori; H Nara; N Kaneko; Y Shirota; A Takeda; J Masuyama; T Yoshio; S Kano; S Minota
Journal:  Nihon Rinsho Meneki Gakkai Kaishi       Date:  2000-02

4.  Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin--a preliminary report.

Authors:  Y Levy; Y Sherer; P Langevitz; M Lorber; P Rotman; F Fabrizzi; Y Shoenfeld
Journal:  Clin Rheumatol       Date:  2000       Impact factor: 2.980

5.  Skin score. A semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosis.

Authors:  P J Clements; P A Lachenbruch; S C Ng; M Simmons; M Sterz; D E Furst
Journal:  Arthritis Rheum       Date:  1990-08

6.  Treatment of severe localized scleroderma by plasmapheresis--report of three cases.

Authors:  F Wach; H Ullrich; G Schmitz; M Landthaler; R Hein
Journal:  Br J Dermatol       Date:  1995-10       Impact factor: 9.302

7.  Immune modulation during treatment of systemic sclerosis with plasmapheresis and immunosuppressive drugs.

Authors:  P C Dau; J P Callahan
Journal:  Clin Immunol Immunopathol       Date:  1994-02

8.  Myeloperoxidase-specific anti-neutrophil cytoplasmic autoantibodies -- related scleroderma renal crisis treated with double-filtration plasmapheresis.

Authors:  A Omote; M Muramatsu; Y Sugimoto; S Hosono; R Murakami; H Tanaka; Y Watanabe; H Sano; K Kato
Journal:  Intern Med       Date:  1997-07       Impact factor: 1.271

9.  Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study.

Authors:  F Nacci; A Righi; M L Conforti; I Miniati; G Fiori; D Martinovic; D Melchiorre; T Sapir; M Blank; Y Shoenfeld; A Moggi Pignone; M Matucci Cerinic
Journal:  Ann Rheum Dis       Date:  2007-03-07       Impact factor: 19.103

  9 in total
  9 in total

1.  Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis.

Authors:  Corrie L Poelman; Laura K Hummers; Fredrick M Wigley; Cynthia Anderson; Francesco Boin; Ami A Shah
Journal:  J Rheumatol       Date:  2014-11-29       Impact factor: 4.666

Review 2.  Intravenous immunoglobulins (IVIG) in systemic sclerosis: a challenging yet promising future.

Authors:  Luca Cantarini; Donato Rigante; Antonio Vitale; Salvatore Napodano; Lazaros I Sakkas; Dimitrios P Bogdanos; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2015-03       Impact factor: 2.829

Review 3.  Intravenous immunoglobulins for treatment of connective tissue diseases in dermatology.

Authors:  Lyubomir A Dourmishev; Dimitrina V Guleva; Ljubka G Miteva
Journal:  Wien Med Wochenschr       Date:  2017-09-01

Review 4.  Intravenous immunoglobulin therapy in rheumatic diseases.

Authors:  Jagadeesh Bayry; Vir Singh Negi; Srini V Kaveri
Journal:  Nat Rev Rheumatol       Date:  2011-05-10       Impact factor: 20.543

Review 5.  Benefits and limitations of plasmapheresis in renal diseases: an evidence-based approach.

Authors:  Sanjeev Baweja; Kate Wiggins; Darren Lee; Susan Blair; Margaret Fraenkel; Lawrence P McMahon
Journal:  J Artif Organs       Date:  2010-12-10       Impact factor: 1.731

6.  [Towards an implementation of guidelines for the therapy of systemic sclerosis (scleroderma): between desire and reality].

Authors:  M O Becker; U Müller-Ladner; G Riemekasten
Journal:  Z Rheumatol       Date:  2010-06       Impact factor: 1.372

7.  The role of intravenous immunoglobulin preparations in the treatment of systemic sclerosis.

Authors:  Marta Baleva; Krasimir Nikolov
Journal:  Int J Rheumatol       Date:  2011-11-02

Review 8.  Therapeutic plasma exchange for the treatment of systemic sclerosis: A comprehensive review and analysis.

Authors:  Edward S Harris; Herbert J Meiselman; Patrick M Moriarty; Allan Metzger; Miroslav Malkovsky
Journal:  J Scleroderma Relat Disord       Date:  2018-03-09

9.  Sustained benefit from combined plasmapheresis and allogeneic mesenchymal stem cells transplantation therapy in systemic sclerosis.

Authors:  Huayong Zhang; Jun Liang; Xiaojun Tang; Dandan Wang; Xuebing Feng; Fan Wang; Bingzhu Hua; Hong Wang; Lingyun Sun
Journal:  Arthritis Res Ther       Date:  2017-07-19       Impact factor: 5.156

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.